Monday, Viracta Therapeutics Inc (NASDAQ:VIRX) reported topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from both arms of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort.
Patients were randomized to either nanatinostat monotherapy (n=10) or nanatinostat in combination with valganciclovir (Nana-val, n=10).
Nana-val (nanatinostat in combination with valganciclovir) demonstrated greater efficacy than nanatinostat monotherapy and was generally well-tolerated. The median duration of response continues to ...